SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VGNX -- Variagenics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (108)1/18/2002 12:52:26 PM
From: keokalani'nui  Respond to of 269
 
I hope he would say:

"We are so far ahead in clinical analysis and have undertaken such a more thorough understanding of colorectal disease response to multiple treatment in varied disease stages, that when we start stamping out the assays, we will blow the doors off TWIT's carriage."

Unfortunatley the earliest that statement could be made is late this year. I hope Crouch's voice drops by then; brilliant, dedicated and honest he may be but he sounds too nice and too young for this business!

Wilder



To: scaram(o)uche who wrote (108)1/18/2002 12:55:15 PM
From: tuck  Read Replies (1) | Respond to of 269
 
>>why didn't VGNX get this deal?<<

They might as well have. VGNX up almost 10% and TWTI treading water as I type. Sheesh. I know some investors are dyslexic, per your cute COR/CORR trade, but I really don't get this reaction. Not that I mind: though I just bought a little TWTI, I own a lot more VGNX. Anyhow, TWTI is very active in Japan, FWIW.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News